5 citations
,
June 2019 in “Open Forum Infectious Diseases” This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.
September 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This paper reviews the diverse skin, nail, and hair changes caused by medications, highlighting hyperpigmentation, alopecia, and nail structural alterations, but reports no new data.
4 citations
,
February 2013 in “Revista De Saude Publica” This article examines the public health risks and benefits of pill organizers and cutters, concluding that healthcare professionals should guide their use to prevent potential medication stability and efficacy issues.
July 2018 in “Elsevier eBooks” This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.
3 citations
,
September 2020 in “Molecular Brain” This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.
